



1H FY26 Results Webinar

9th February 2026

Epiminder Limited (ASX:EPI) (**Epiminder** or the **Company**), a pioneer medical device company developing breakthrough epilepsy monitoring technology, advises that the results for the six months ending 31 December 2025 ('1H FY26') will be released on 25th February 2026.

Investors and potential investors are invited to join a webinar at 9:00am on Wednesday 25th February 2026 via the link below

[Epiminder 1H FY26 Results](#)

+++

Authorisation

This announcement has been authorized for lodgement to the ASX by Epiminder's Chief Financial Officer.

For any Company queries please contact Epiminder at investors@epiminder.com

Follow Epiminder on [LinkedIn](#) and explore [Epiminder.com](#) for more information.

About Minder

Minder is a minimally invasive device for continuous monitoring of electrographic activity of the brain, providing epilepsy patients and their doctors with detailed data on brain activity over an extended period. Patients can wear the device as they go about their normal daily activities.

Minder's long-term monitoring of patients outside a controlled clinical environment provides clinicians with the data needed to remotely monitor and assess the patient's underlying condition, including the effectiveness of drug therapies and other interventions.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.